8:30 am Keynote Presentation: A Review of the Past 12 Months in Cannabinoid Pharmaceutical Development

Sourcing, Extraction and Synthesis of Cannabinoid for Research

9:00 am The Evolving Cannabinoid API Market: Disruption for Some, Normal Course for Most

9:30 am Advancements in Cannabinoid-Derived Active Pharmaceutical Ingredients Towards Regulatory Approval

10.00 Speed Networking and Morning Break

10:30 am

Early Stage Drug Development Track

Clinical Development Track

Discovering the Next Generation of Novel Cannabinoid Pharmaceuticals

Using new discoveries in cannabinoid pharmacology and receptor biology to discover new therapeutics

Overcoming Clinical Trial Design Challenges for Greater  Reliability

Improve clinical outcomes at all stages and assemble data for regulatory review

10.30 New Insights and Data on the Structure and Function of CB2

  • The crystal structure of the human cannabinoid CB2 reveals how small molecules affect CB2 differently
  • Structural analysis reveals a high degree of conformational similarity with the agonist bound CB1
  • Foreseeing the yin-yang relationship of CB2 & CB2 facilitating the design of selective drugs

Alex Makriyannis, Director, Center for Drug Discovery, Northeastern University

10.30 CBD as a Pharmaceutical: Requirements and Phase 1 Clinical Trial Results

  • Increasing the oral bioavailability of CBD, in a manner acceptable to regulatory authorities in the United States and elsewhere, is essential to making it a reliable medicine
  • A Phase 1 PK shows confirms that ANANDA Scientific’s uniquely enhanced CBD, or Liquid StructureTM CBD, rapidly and prodigiously enters the body, with Tmax at 1 hour instead of the 2-3 hours seen with regular CBD
  • Liquid Structure CBD may have a desirably heightened pharmacodynamic impact than does regular CBD, especially evidenced by sizable reductions in TNF-α, an inflammation protein associated with many autoimmune diseases as well as the deadly cytokine storms that outfall COVID-19 and influenza infection

Mark Rosenfeld, Chief Executive Officer & Chief Science Officer, Ananda Scientific

11.00 Taking Aim at the ECS with Novel  Small Molecules

Drug discovery - How small molecules can elicit effects at the endocannabinoid system:

  • Small molecule drugs based upon THC’s structure have been developed to interact directly with CB1 and/or CB2 receptors, or impose allosteric modulation of the receptor responses to endocannabinoids or agonist drugs
  • Small molecule drugs are being developed to intervene at synthesis, transport or metabolism of endocannabinoids, and thereby alter the body’s normal or pathological processes
  • Drug interactions could arise due to Cannabis natural products competition with small molecule medicines that intervene at ECS processes

Allyn Howlett, Professor, Wake Forest School of Medicine

11.00 Cannabinoids delivered as novel solid dosage forms – Proof-of-Concept Clinical Data

  • The effectiveness of cannabinoid medicines is negatively impacted by very low bioavailability, highly variable absorption, and erratic time to onset
  • Currently available cannabinoid dosage forms attempt to compensate for some of these deficiencies with high doses that have the potential to produce undesirable side effects
  • Receptor is developing solid dosage forms, both oral and inhaled, that address all of these cannabinoid delivery challenges. Data from 2 initial, proof-of-concept clinical studies will demonstrate the feasibility of this approach

Andrea Leone-Bay, Chief Scientific Officer and Founder, Receptor Life Sciences

11.30 Drug Target Prediction and Development Using an Integrated Computational and High-Throughput Screening Approach

  • Power of computational biology and machine learning for cannabinoid screening and optimization as a drug substance
  • Drug product development through multiple differentiating, consistent and reliable formulation and delivery technologies
  • Evidence-based medicine based on robust pre- and clinical development

Saeid Babaei, Chief Executive Officer, Orpheus Medica

11.30 A Fact-Based Approach to Training Medical Providers on the ECS: Demystifying Common Myths & Misconceptions of Medical Cannabis

  • Describe the history of didactic ECS coverage for medical professionals
  • Discuss evidence-based remedial strategies for prevalent misinformation
  • Summarize implementable patient and medical provider educational tools

Monica Taing, Board Member, Doctors for Cannabis Regulation

12:00 Discovery of novel CB2 Selective Agonists for the Treatment of Inflammation and Fibrosis

  • Design and structure-activity relationships of novel CB2 selective ligands
  • CB2 receptor-ligand complex structural characteristics for agonist vs antagonist
  • Anti-inflammatory and anti-fibrotic activities of potential candidate compounds

Hongfeng Deng, Director & Head of Medicinal Chemistry, Corbus Pharmaceuticals Holdings Inc.

12:00 How can you Accelerate and Support the Clinical Development of Therapeutic Developers in this space?

The cannabinoid derived drug development industry is facing multiple roadblocks impeding the demonstration of clinical utility in pipeline candidates

Highlight your proven track record facilitating and accelerating the delivery of therapeutics with target efficacy and safety profiles

Position yourself as the partner of choice in this fast paced and expanding industry

Enquire today to find how you can get involved and contact:

Nicholas Ramovic, Partnerships Director
@: sponsor@hansonwade.com
T: +44 (0)20 3141 8700

12:30 pm Lunch and Networking

1:30 pm

Preclinical Testing for Safety and Efficacy of Potential Therapeutics

Explore methods and technologies that will increase confidence in the clinical potential of cannabinoid therapeutics

Building Strong Clinical Trial Delivery and Patient Selection Strategies

Discuss the key principles that come into play when selecting a site for phase 1 trials

13.30 Rational Design of Cannabinoid-Containing Complex Mixtures and Establishing Proof of Concept for Disease-Specific Applications

  • To discover novel disease-specific therapies, GBS utilizes rational design principles in creating Cannabinoid-Containing Complex Mixtures targeting the endocannabinoid system. GBS incorporates data from high throughput experiments using disease-specific cell and animal models that are combined with computer models of receptor-interactions in a predictive network pharmacology-based algorithm
  • The bioavailability of GBS’ Cannabinoid-Containing Complex Mixtures is enhanced using novel oral delivery systems including: a. oral dissolving tablets, b. time-released nanoparticles for oral administration, c. oral thin films, and d. gel capsules
  • Using an animal model of the disease, Proof of Concept has been established for GBS’ Parkinson’s disease therapy and the Mechanism of Action is being explored

Andrea Lee Small-Howard, Chief Science Officer, Director & Board Member, GBS Global Biopharma, Inc./GB Sciences, Inc.

13:30 Identifying Potential Sites for Trials and Setting Up Clinical Operations in Foreign Regulatory: Insights from a Phase 2a clinical trial in Insomnia

  • Results from a Phase2 study assessing the safety and efficacy of a novel plant-derived medicinal cannabis oral formulation in patients with insomnia
  • Two weeks of nightly sublingual administration of a cannabinoid extract (ZTL-101) significantly improved insomnia symptoms, sleep quality and daytime fatigue, and capacity to engage in everyday tasks
  • The cannabinoid extract (ZTL-101) was associated with an acceptable short-term safety profile

Richard Hopkins, Managing Director ex USA, Zelira Therapeutics

14.00 Identifying and Validating Mechanism of Action of Action In vivo/vitro

  •  Identification of specific cannabinoids enhancing the immunogenicity of tumour cells and subsequent development of a potent selective compound for glioblastoma - PAS-403
  • In vitro: Data showing the PAX-403 exerts its MOA as a mitotic inhibitor binding to the colchicine site of tubulin
  • In vivo: AS-403 synergizes with radiation or Temozolomide in a mouse model of glioblastoma

Patrick Gray, CEO, Pascal Biosciences

14.00 Utilizing Diagnostics in Cannabinoid Medicine for Oncology

  • A look into the clinical applications of Vrypharm Biopharmaceutical’s patented comprehensive medical cannabis and hemp testing methodology platform
  • Employing diagnostics to improve the clinical management in oncology patients where cannabinoid medicines are recommended

Jerry Bryant, CSO, Vyripharm Biosciences

14.30 Panel Discussion: Achieving the Ideal Pharmacokinetic and Pharmacodynamic Profiles in Drug Formulation

  •  Understand how to leverage preclinical data to improve your formulation
  • Implement preclinical insights for the best clinical outcomes

Andrea Lee Small-Howard, Chief Science Officer, Director & Board Member, GBS Global Biopharma, Inc./GB Sciences, Inc.

Patrick Gray, CEO, Pascal Biosciences

Manuel de Pra, Research & Development Coordinator, Entourage Phytolab

14.30 Clinical Trial Design, Endpoints and Regulatory Strategies

  • A look into the ART27.13 program, a high potency GPCR agonist for anorexia associated with cancer
  • The importance of consultation with regulatory authorities throughout the progression of clinical development
  • Challenges, approaches and critical path activities when developing cannabinoid derived pharmaceuticals

Andy Yates', Chief Scientific Officer, Artelo Biosciences

15:00 Can you help drive pipelines to clinical success?

Drug developers are seeking insight into how they can prime themselves for clinical trials.

Accessing the best formulation options and effectively testing drug safety profiles is of critical importance to this community.

Find out how best you can showcase your expertise to this captive audience by reaching out to:

Nicholas Ramovic, Partnerships Director
@: sponsor@hansonwade.com & US number only

15.00 Panel Discussion: Overcoming the Major Hurdles in Clinical Trials

  •  Understand strategies to identify and train capable investigators
  •  Recruit appropriate patients while maintaining timelines
  • Understand the differences in therapeutic endpoints and study success

Richard Hopkins, Managing Director ex USA, Zelira Therapeutics

Steven James, Clinical Assistant Professor, Steven James MD

Mark Rosenfeld, Chief Executive Officer & Chief Science Officer, Ananda Scientific

Andrea Leone-Bay, Chief Scientific Officer and Founder, Receptor Life Sciences

3:30 pm Afternoon Break and Poster Session

Enhancing Bioavailability, Efficacy and Safety Through Formulation

4:00 pm Investigating How PK/PD is Affected by Method of Delivery through Controlled Dosing

  • Ryan Vandrey Associate Professor, Johns Hopkins University

4:30 pm Optimizing Method of Delivery to Maximise Efficiency of Administration

5:00 pm End of Day One and Drinks Reception